Concurrent chemo-radiotherapy with taxotere and cisplatin in head and neck cancer: A feasibility study

Anticancer Research

Volumn 25, Issue 6 C, 2005, Pages 4451-4454

  Mencoboni, M ^a   Rebella, L ^b   Tredici, S ^a   Ghio, R ^b   Scarpati, D ^c   Bavazzano, M ^c   Jankowska, B ^c   Delle Piane, M ^c  

^a VILLA SCASSI HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Chemo radiotherapy; Cisplatin; Head and neck cancer; Taxotere

Indexed keywords

CISPLATIN; DOCETAXEL;

ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HEAD CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NECK CANCER; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME;

AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; TAXOIDS;

EID: 28444476553     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Grandis JR, Pietenpol JA, Greenberger JS, Pelroy RA and Mohla S: Head and neck cancer: meeting summary and research opportunities. Cancer Res 64(21): 8126-8129, 2004.
2. Jeremic B, Milicic B, Dagovic A, Vaskovic Z and Tadic L: Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck. J Clin Oncol 22(17): 3540-3548, 2004.
3. Psyrri A, Kwong M, DiStasio S, Lekakis L, Kassar M, Sasaki C, Wilson LD, Haffty BG, Son YH, Ross DA, Weinberger PM, Chung GG, Zelterman D, Burtness BA and Cooper DL: Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. J Clin Oncol 22(15): 3061-3069, 2004.
4. Beckmann GK, Hoppe F, Pfreundner L and Flentje MP: Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head Neck 27(1): 36-43, 2005.
5. Fountzilas G, Ciuleanu E, Dafni U, Plataniotis G, Kalogera-Fountzila A, Samantas E, Athanassiou E, Tzitzikas J, Ciuleanu T, Nikolaou A, Pantelakos P, Zaraboukas T, Zamboglou N, Daniilidis J and Ghilezan N: Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study. Med Oncol 21(2): 95-107, 2004.
6. Bourhis J, Calais G, Lapeyre M, Tortochaux J, Alfonsi M, Sire C, Bardet E, Rives M, Bergerot P, Rhein B and Desprez B; French Head and Neck Cancer Group (GORTEC): Concomitant radiochemotherapy or accelerated radiotherapy: analysis of two randomized trials of the French Head and Neck Cancer Group (GORTEC). Semin Oncol 31(6): 822-826, 2004, review.
7. Huguenin P, Beer KT, Allal A, Rufibach K, Friedli C, Davis JB, Pestalozzi B, Schmid S, Thoni A, Ozsahin M, Bernier J, Topfer M, Kann R, Meier UR, Thum P, Bieri S, Notter M, Lombriser N and Glanzmann C: Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 22(23): 4665-4673, 2004.
8. Erratum in: Huguenin P, Beer KT, Allal A, Rufibach K, Friedli C, Davis JB, Pestalozzi B, Schmid S, Thoni A, Ozsahin M, Bernier J, Topfer M, Kann R, Meier UR, Thum P, Bieri S, Notter M, Lombriser N and Glanzmann C: J Clin Oncol 23(1): 248, 2005.
9. Varveris H, Mazonakis M, Vlachaki M, Kachris S, Lyraraki E, Zoras O, Maris T, Froudarakis M, Velegrakis J, Perysinakis C, Damilakis J and Samonis G: A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck. Oncol Rep 10(1): 185-195, 2003.
10. Suzuki M, Nishimura Y, Nakamatsu K, Kanamori S, Koike R, Kawamoto M and Mori K: Phase I study of weekly docetaxel infusion and concurrent radiation therapy for head and neck cancer. Jpn J Clin Oncol 33(6): 297-301, 2003.
11. Calais G, Bardet E, Sire C, Alfonsi M, Bourhis J, Rhein B, Tortochaux J, Man YT, Auvray H and Garaud P: Radiotherapy with concomitant weekly docetaxel for Stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC phase II trial. Int J Radiat Oncol Biol Phys 58(1): 161-166, 2004.
12. Nabell L and Spencer S: Docetaxel with concurrent radiotherapy in head and neck cancer. Semin Oncol 30(6 Suppl 18): 89-93, 2003, review.
13. Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Ferreli L, Camboni P, Lusso MR, Mocci M, Madeddu C, Mura L, Mudu MC, Proto E, Tore G, Mura M, Maccio A, Ferreli A and Amichetti M: Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: a phase II study with organ-sparing purposes. Oncol Rep 10(3): 759-766, 2003.
14. Airoldi M, Cattel L, Cortesina G, Giordano C, Pedani F, Recalenda V, Danova M, Gabriele AM, Tagini V, Porta C and Bumma C: Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck: pharmacokinetic and clinical data of a phase I-II study. Am J Clin Oncol 27(2): 155-163, 2004.
15. Ghi MG, Paccagnella A, D'Amanzo P, Mione CA, Fasan S, Paro S, Mastromauro C, Carnuccio R, Turcato G, Gatti C, Pallini A, Nascimben O, Biason R, Oniga F, Medici M, Rossi F and Fila G: Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study. Int J Radiat Oncol Biol Phys 59(2): 481-487, 2004.
16. Karasawa K, Shinoda H, Katsui K, Seki K, Kohno M, Hanyu N, Nasu S, Muramatsu H, Maebayashi K, Mitsuhashi N and Yoshihara T: Radiotherapy with concurrent docetaxel and carboplatin for head and neck cancer. Anticancer Res 22(6B): 3785-3788, 2002.
17. Langenberg M, Terhaard CH, Hordijk GJ, Es RJ, Voest EE and Graeff A: Simultaneous radio- and chemotherapy for squamous cell carcinoma of the head and neck in daily clinical practice: 5 years experience in a university hospital. Clin Otolaryngol Allied Sci 29(6): 729-734, 2004.
18. Langendijk JA, Leemans ChR, Buter J, Berkhof J and Slotman BJ: The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 22(22): 4604-4612, 2004.
19. Haddad RI, Tishler R, Wirth L, Norris C, Goguen L, Sullivan C, O'Donnell L, Li Y and Poster MR: Role of complete pathological responses to docetaxel/cisplatin/5-Fluorouracil induction chemotherapy in patients with newly diagnosed, locally advanced squamous cell carcinoma of the head and neck. ASCO Proceedings 2005, Orlando, ABS 5511.
20. Smaradottir A, Siddiqi C, Ray J, Haider J, Azrin M and Hedge U: Increased incidence of cardiotoxicity after infusional 5-fluorouracil, cisplatin and docetaxel combination chemotherapy in patients with locally advanced head and neck cancer. ASCO Proceedings 2005, Orlando, ABS 5568.
21. Argiris A, Goldwasser MA, Brockstein B, Axelrod R and Forastiere A: Weekly docetaxel amd irinotecan in patients with recurrent or metastatic head and neck cancer. A phase II trial of the Eastern Cooperative Oncology Group (ECOG). ASCO Proceedings 2005, Orlando, ABS 5528.
22. Kim ES, Kies M, Sabichi A, Ginsberg L, Burke B, Holsinger C, Feng L, Truong MT, Glisson B and Hong WK: Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic or recurrent head and neck squamous cell carcinoma. ASCO Proceedings 2005, Orlando, ABS 5546.
23. Axelrod RS, Machtay M, Anna PR, Dicker A, Sidhu K, Jacobs M, Rosen M and Keane W: Phase I study of weekly docetaxel, cisplatin with daily celecoxib and concurrent radiotherapy for patients with locally advanced head and neck cancer. ASCO Proceedings 2005, Orlando, ABS 5598.